Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.

Nature medicine·2026
Same author

A reassessment of anti-CAR T-cell expansion strategies.

Blood·2026
Same author

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026
Same author

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Transplantation and cellular therapy·2026
Same author

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Focused ultrasound-enhanced cell therapy for brain tumors: Summary of roundtable discussions.

Neuro-oncology advances·2026

Related Experiment Video

Updated: Mar 11, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K

EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.

Lauren P McLaughlin1,2, Stephen Gottschalk3, Cliona M Rooney4

  • 1Department of Hematology/Oncology, Children's National Medical Center, 111 Michigan Ave., Washington, DC, 20010, USA. lmclaugh@childrensnational.org.

Methods in Molecular Biology (Clifton, N.J.)
|November 23, 2016
PubMed
Summary

Epstein Barr virus (EBV) specific T cell therapies are crucial for treating EBV-associated lymphomas. This study details a method for manufacturing EBV-specific T cell products targeting LMP1 and LMP2 antigens.

Keywords:
Adoptive T cell therapyEpstein Barr virusGood manufacturing practiceLymphoma

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Related Experiment Videos

Last Updated: Mar 11, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Area of Science:

  • Virology
  • Immunology
  • Oncology

Background:

  • Epstein Barr virus (EBV) establishes latency in B cells, causing mild illness but also linked to malignancies like lymphomas.
  • EBV antigens on lymphoma cells are targets for adoptive T cell therapy.
  • Subdominant EBV antigens limit therapeutic efficacy, necessitating strategies targeting dominant antigens like LMP1 and LMP2.

Purpose of the Study:

  • To describe a method for generating Good Manufacturing Practice (GMP)-compliant EBV-specific T cell products.
  • To focus on manufacturing T cell products targeting Latent Membrane Protein 1 (LMP1) and LMP2.

Main Methods:

  • Focuses on a specific method for manufacturing EBV-specific T cell products.
  • Details the generation of GMP-compliant T cell products.
  • Enriches T cell products for LMP1 and LMP2 specificity.

Main Results:

  • The described method yields GMP-compliant EBV-specific T cell products.
  • The products are enriched for specificity against LMP1 and LMP2 antigens.
  • This approach addresses the need for targeting subdominant EBV antigens in lymphoma treatment.

Conclusions:

  • The presented method offers a viable strategy for producing EBV-specific T cell therapies.
  • Targeting LMP1 and LMP2 enhances the potential efficacy of adoptive T cell therapy for EBV-associated lymphomas.
  • This work contributes to the development of novel treatments for EBV-driven malignancies.